

## ORIGINAL RESEARCH

Pediatric Urology

Doi: 10.4274/jus.1902

Journal of Urological Surgery, 2018;5(4):176-181

# Assessment of Serotonin Metabolite 5-hydroxyindoleacetic Acid Levels in Urine Sample for Diagnosis and Treatment Efficacy in Children with Dysfunctional Voiding and Their Interaction with Biofeedback Therapy

Disfonksiyonel İşemeli Çocukların Tanısında ve Tedavi Etkinliğinin Değerlendirilmesinde Serotonin Metaboliti İdrar 5-hidroksiindolasetik Asit Düzeyleri ve Biofeedback Tedavisi ile Etkileşimi

 Bahadır Topuz<sup>1</sup>,  Giray Ergin<sup>2</sup>,  Burak Köprü<sup>2</sup>,  Turgay Ebioloğlu<sup>1</sup>,  Hasan Cem Irkılata<sup>3</sup>,  Yusuf Kibar<sup>2</sup>,  
 Musa Murat Dayanç<sup>2</sup>

<sup>1</sup>University of Health Sciences, Gülhane Training and Research Hospital, Clinic of Urology, Ankara, Türkiye

<sup>2</sup>Koru Hospital, Clinic of Urology, Ankara, Türkiye

<sup>3</sup>Davraz Yaşam Hospital, Clinic of Urology, Isparta, Türkiye

## What's known on the subject? and What does the study add?

Dysfunctional voiding is one of the childhood urological problems that constitute a serious problem for families and children. We still do not know if a problem at the level of neurotransmitter metabolite in the central nervous system plays a role in the etiology of dysfunctional voiding. New studies are needed to get more information about the role of neuromodulators in the etiology and treatment of dysfunctional voiding. Therefore, this study will be beneficial for researchers in shaping the relationship between dysfunctional voiding and neuromodulators.

## Abstract

**Objective:** Dysfunctional voiding (DV), which is explained as an incoordination between the external urethral sphincter and the bladder, is a situation developing in neurologically normal children. Serotonin has some effects on the lower urinary tract which cannot be fully explained. The selective 5-hydroxyindoleacetic acid (5-HIAA) agonist improves voiding efficacy in the rat model with voiding dysfunction as serotonin. Serotonin decomposes to 5-HIAA which excreted from urine. We considered that a problem in neuromodulator levels can lead to DV and evaluated the levels of 5-HIAA in urine.

**Materials and Methods:** Our study included 130 children aged 5-15 years who were diagnosed with DV and 48 children with no urological complaints as controls. Urine samples were taken only once in control group, and 3 times [before and after the biofeedback treatment (sixth month and twelfth month)] in the study group to determine the difference and the interaction between 5-HIAA and biofeedback therapy.

**Results:** Biofeedback therapy was found to be an effective method in the treatment of DV. However, there was no significant difference in the level of mean urine 5-HIAA/creatinine (u5-HIAA/Cr) between study (6.139±3.652) and control groups (6.374±4.329) (p=0.751). The mean u5-HIAA/Cr levels in the DV group at baseline and at the end of biofeedback therapy (6<sup>th</sup> month) were 6.249±4.132 and 6.19±4.715, respectively (p=0.951). The mean u5-HIAA/Cr levels in the DV group at baseline and at 12 months were 5.901±3.291 and 6.644±4.206, respectively (p=0.557). There was no significant difference in u5-HIAA/Cr levels between pre-treatment and post-treatment in the DV group.

**Conclusion:** We still do not know if a problem at the level of neurotransmitter metabolite in the central nervous system plays a role in the etiology of DV. We evaluated this relationship, but we could not find a significant result. New studies are needed to get more information about the role of neuromodulators in the etiology and treatment of DV.

**Keywords:** Biofeedback therapy, Dysfunctional voiding, 5-hydroxyindoleacetic acid, Serotonin

**Correspondence:** Bahadır Topuz MD, University of Health Sciences, Gülhane Training and Research Hospital, Clinic of Urology, Ankara, Türkiye

**Phone:** +90 312 304 56 07 **E-mail:** drbttopuz@gmail.com **ORCID-ID:** orcid.org/0000-0001-6209-803X

**Received:** 10.01.2018 **Accepted:** 25.06.2018

**Cite this article as:** Topuz B, Ergin G, Köprü B, Ebioloğlu T, Irkılata HC, Kibar Y, Dayanç MM. Assessment of Serotonin Metabolite 5-hydroxyindoleacetic Acid Levels in Urine Sample for Diagnosis and Treatment Efficacy in Children with Dysfunctional Voiding and Their Interaction with Biofeedback Therapy. *J Urol Surg* 2018;5(4):176-181.

©Copyright 2018 by the Association of Urological Surgery / Journal of Urological Surgery published by Galenos Publishing House.



## Öz

**Amaç:** Disfonksiyonel işeme (Dİ), nörolojik olarak normal çocuklarda gelişen bir durumdur ve dış üretral sfinkter ile mesane arasındaki koordinasyonsuzluk olarak açıklanmaktadır. Serotoninin alt üriner sistem üzerinde tam olarak açıklanamayan bazı etkileri vardır. Selektif 5-hidroksiindolasetik asit (5-HIAA) agonisti, serotonin gibi işeme disfonksiyonu olan sıçan modelinde işeme etkinliğini geliştirir. Serotonin 5-HIAA'ya parçalanarak idrar ile atılır. Nöromodülatör düzeylerindeki bir sorunun Dİ etiolojisine yol açabileceğini düşünüyorduk ve idrardaki 5-HIAA düzeylerini değerlendirdik.

**Gereç ve Yöntem:** Çalışmamız Dİ tanısı konulan 5-15 yaş arasındaki 130 çocuk ile 2013 ve 2015 yılları arasında planlandı. İdrar numuneleri, kontrol grubunda sadece bir kez ve çalışma grubunda biofeedback tedavisi ile olan farkı ve etkileşimi belirlemek için 3 kez [biofeedback tedavisinden önce ve sonra (altıncı ay ve on ikinci ay)] alındı.

**Bulgular:** Biofeedback tedavisinin Dİ'de etkili bir yöntem olduğu bulundu. Ancak çalışma (6,139±3,652) ve kontrol grubu (6,374±4,329) arasında ortalama idrar 5-HIAA/kreatinin (u5-HIAA/Cr) düzeyinde anlamlı farklılık yoktu (p=0,751). Dİ grubunda, biofeedback tedavisinin başlangıcında ve sonundaki (6. ay) ortalama u5-HIAA/Cr düzeyleri sırasıyla 6,249±4,132 ve 6,19±4,715 idi (p=0,951). Dİ grubunda, biofeedback tedavisinin başlangıcında ve on ikinci ayda ortalama u5-HIAA/Cr düzeyleri sırasıyla 5,901±3,291 ve 6,644±4,206 idi (p=0,557). Dİ grubunda tedavi öncesi ve sonrası u5-HIAA/Cr düzeyleri arasında anlamlı fark yoktu.

**Sonuç:** Dİ etiolojisinde merkezi sinir sisteminde nörotransmitter metaboliti seviyesinde bir sorun olup olmadığını hala bilmiyoruz. Bu ilişkiyi değerlendirdik, ancak önemli bir sonuç bulamadık. Dİ etiolojisi ve tedavisinde nöromodülatörlerin rolü hakkında daha fazla bilgi edinmek için yeni çalışmalara ihtiyaç vardır.

**Anahtar Kelimeler:** Biofeedback tedavisi, Disfonksiyonel işeme, 5-hidroksiindolasetik asit, Serotonin

## Introduction

Dysfunctional voiding (DV) is a situation that occurs in neurologically normal children during toilet training period and explained as an incoordination between the external urethral sphincter and the bladder (1). Actually, it occurs as a result of wrong voiding habits (2).

In the standardization article published by International Children's Continence Society in 2016, various sub-types regarding the storage and voiding phase of lower urinary tract dysfunction (LUTD) are determined (1). Accordingly, overactive bladder, underactive bladder, DV and bladder neck dysfunction included in the sub-types of LUTD. In addition, LUTD is present in more rare subtypes such as voiding postponement, vaginal reflux, Hinman syndrome, bladder outlet obstruction, and giggle incontinence. DV is a voiding phase disease. DV symptoms may include hesitancy, straining, intermittency, dysuria, holding maneuvers, increased voiding frequency, incontinence, urgency, nocturia, and constipation (1). There is a pelvic floor activity in DV, which is manifested by a staccato and/or interrupted pattern in uroflowmetry with simultaneous electromyography (UF-EMG) (3). DV can lead to recurrent urinary tract infection, vesicoureteral reflux and chronic renal failure in children (4). DV can be evaluated with detailed history, physical examination, 3-day-bladder diary, urinary ultrasonography, the DV and Incontinence Symptoms Score (DVISS), UF-EMG, and post-void residual urine (PVR) measurement without a need for invasive examinations (5).

In the central nervous system (CNS), serotonin and other neuromodulators have some effects on lower urinary tract storage and emptying, however, they could not be fully demonstrated till now (6,7). Serotonergic neurons in the CNS are located

mainly in the raphe nuclei in the brain stem. Serotonin, which is synthesized in serotonergic nerve endings, is stored together with other substrates in vesicles (8). Serotonin decomposes to 5-hydroxyindoleacetic acid (5-HIAA) by monoamine oxidase which is excreted via urine (9). Serotonergic neural transport is regulated by serotonin receptors (5-HT). Studies on voiding function are related to the 5HT<sub>1A</sub> receptor. It has been shown that 5-HT<sub>1A</sub> receptor agonist 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) injected in anesthetized rats with DV model activated the voiding reflex, increased the frequency of bladder contractions, increased the voiding volume, reduced bladder capacity, reduced intravesical pressure, and decreased PVR (10). The 5-HT<sub>1A</sub> agonist 8-OH-DPAT administered to rats with spinal cord injury increased the external urethral sphincter relaxation period (11). Serotonin and 5-HIAA levels may be important in children with DV.

In this study, we consider that a problem in neuromodulator levels in CNS can lead to DV. We aimed to examine the value of serotonin metabolite 5-HIAA levels in urine sample for diagnosis and assessment of treatment efficacy in children with DV and their interaction with biofeedback therapy.

## Materials and Methods

This study was approved by the Gülhane Military Medical Academy Ethics Committee (approval number: 15, date: 3 April 2013) and followed the Institution's Review Board of Human Subject Guidelines. Consent form was filled out by all participants. Our study was designed as prospective, double blind and controlled study including 130 children aged 5-15 years who attended our urology department from April 2013 to April 2015. A thorough physical examination including the urogenital system and neurological system was conducted.

All patients were evaluated by urinalysis, urine culture, serum urea and creatinine, lumbosacral spine radiography, and urinary ultrasonography.

Thirteen patients, who were diagnosed with urolithiasis, persistent recurrent urinary tract infections and syringomyelia, were excluded from the study. Families of 117 children who participated in the study filled the DVISS questionnaire and 3-day-voiding diary. Forty-eight children had no urological complaints and the DVISS was below 9. In fact, these children consisted of those who attended the pediatric outpatient clinic for height and weight measurements and were directed to our study. DV was not considered in these children and were selected as the control group. Sixty-nine children with a DVISS of 9 or greater, who had a staccato voiding pattern and presence of EMG activity in UF-EMG test and a PVR greater than 20 cc, were evaluated as having DV. UF-EMG (MMS USA, Inc., 383 Central Ave., Suite LL40 Dover, NH 03820, USA) and PVR measurements were conducted for at least twice to confirm the diagnosis of DV in 69 children. UF-EMG was conducted by an experienced technician. PVR was measured with a BladderScan BVI 6100 (Diagnostic Ultrasound, Bothell, WA, USA). DV was evaluated in children without the necessity to use invasive urodynamic studies.

Any situation that would cause a decrease or increase in serotonin and 5-HIAA, such as carcinoid tumor, celiac disease, Whipple disease, cystic fibrosis, bronchial carcinomas, depression, ileum resection, phenylketonuria, Hartnup's disease, and migraine, was included in the exclusion criteria. No detailed diagnostic tests were done for diseases that cause an increase or decrease in serotonin and urine 5-HIAA. To exclude these diseases, the medical history of the family was questioned and a detailed physical examination was performed. Children with spinal cord injury or neurogenic bladder were also excluded from the study.

Children, who were admitted to our outpatient clinic with DV, were taken to biofeedback treatment. The biofeedback treatment protocol, which is well established in our clinical practice, was to take place once a week for the first month. The biofeedback treatment was scheduled for at least six sessions.

The success of biofeedback therapy was evaluated with questioning the patient's symptoms (subjective evaluation criteria) and recovery DVISS, UF-EMG, and PVR (objective evaluation criteria). Urine samples for 5-HIAA levels were taken only once in control group, and 3 times [before and after the biofeedback treatment (6<sup>th</sup> month and 12<sup>th</sup> month)] in the study group to determine the difference and interaction with biofeedback therapy.

Success was defined as an improvement of more than 90% in patients' symptoms.

A 24-hour urine sample is preferred for the measurement of serotonin metabolite and degradation product 5-HIAA in urine. If it is not possible to collect a 24-hour urine sample, a spot urine sample may be used as well as a urine creatinine level. Urine 5-HIAA levels can be normalized by dividing urine creatinine concentrations and the result can be determined as "mg/g creatinine". When urine is collected according to the 24-hour urine procedure, the normal value range for urinary 5-HIAA is 2-8 mg in adults (12). There is no clear data on this value for children. When we examined studies evaluating urinary 5-HIAA levels in children, we saw that they were planned with a spot urine sample (13). We preferred spot urine sample in our study because of the difficulty in collecting and storing 24-hour urine sample in children, parental non-compliance, risk of contamination with defecation, and it was quickly affected by the storage conditions during the molecular collection procedure. However, the spot urine 5-HIAA level (mg/L) was normalized to urine creatinine (mg/dL) and the result was reported as "mg/g creatinine" in order to achieve more accurate results and more valuable study.

Three milliliter urine samples were collected in the morning as the first urine and stored in the refrigerator at -80 °C until the end of the study. Only one urine sample was collected from the children in the control group and kept as in the patient group.

Urine 5-HIAA measurements were made by the high-performance liquid chromatography method (Shimadzu, Japan) in spot urine samples. Measurements were made using an Eureka (Italy) kit in this system. Analyzes were completed with a 50 µL sample injection and a 1.2 mL/min mobile phase flow.

### Statistical Analysis

Statistical analysis was done using the Statistical Package for Social Sciences 15.0 software (SPSS 15.0 for Windows, Chicago, IL, USA). Descriptive statistics were noted with numbers: mean  $\pm$  standard deviation with minimum-maximum. A t-test was used to compare the groups. Categorical variables, expressed as percentages, were analyzed using the McNemar test. We also performed comparisons using the Wilcoxon test for subgroup analysis. A p value of less than 0.05 was considered statistically significant.

### Results

Our study was conducted with a total of 117 children, 69 in the patient group and 48 in the control group. The mean age of the patients was  $8.65 \pm 2.53$  (range: 5-15) years and 16 (23%) of them were boys and 53 (77%) were girls. The mean age of the control group was  $9.20 \pm 2.86$  (range 5-15) years and 26 (54%) of them were boys and 22 (46%) were girls. The results of DVISS for the patient group and the control group are depicted in Figure 1.

The objective parameters such as voiding pattern, UF-EMG and PVR were improved with the success rates of 84% ( $p < 0.001$ ), 63% ( $p < 0.001$ ) and 72% ( $p < 0.001$ ), respectively. We found that in DVISS parameters such as daytime incontinence, enuresis, frequency, straining, dysuria, intermittency, incomplete emptying, urgency, making holding maneuvers, urgency incontinence, and constipation were improved with success rates of 63%, 41%, 56%, 90%, 73%, 68%, 62%, 42%, 58%, 81% and 62%, respectively (Table 1). The mean DVISS in 62 patients before and after biofeedback treatment was found to be  $13.08 \pm 7.34$  and  $5.62 \pm 5.51$  ( $p < 0.001$ ). Twenty-six (50%) of 52




Figure 1. The answered Dysfunctional Voiding and Incontinence Symptoms Score questions for patient and control group

Table 1. Comparison of Dysfunctional Voiding and Incontinence Symptoms Score parameters before and after biofeedback therapies

DVISS questions	Before biofeedback therapy	After biofeedback therapy (6 <sup>th</sup> month)	Success (%)	p*
Daytime incontinence	41	15	63	<0.001
Enuresis	37	22	41	0.001
Frequency	25	11	56	0.013
Straining	10	1	90	0.021
Dysuria	11	3	73	0.039
Intermittency	19	6	68	0.021
Incomplete emptying	13	5	62	0.109
Urgency	48	28	42	<0.001
Making holding maneuvers	36	15	58	<0.001
Urgency incontinence	37	7	81	<0.001
Constipation	13	5	62	0.039

DVISS: Dysfunctional Voiding and Incontinence Symptoms Score  
\*McNemar test

patients whose quality of life was affected before biofeedback treatment had a complete improvement in quality of life ( $p < 0.001$ ).

There was no significant difference in the level of mean urine 5-HIAA/creatinine (u5-HIAA/Cr) between the DV ( $6.139 \pm 3.652$ ) and the control groups ( $6.374 \pm 4.329$ ) ( $p = 0.751$ ) (Table 2).

The u5-HIAA/Cr values in patients in DV and control groups were evaluated in terms of gender. In DV group, the mean u5-HIAA/Cr levels in male and female patients were  $7.353 \pm 3.044$  (3.561-16.247) and  $5.772 \pm 3.765$  (0.84-25.011), respectively ( $p = 0.039$ ). When the pre-treatment u5-HIAA/Cr values were compared in DV group, pre-treatment u5-HIAA/Cr values in females were significantly lower than in males. In control group, the mean u5-HIAA/Cr levels in male and female patients were  $6.57 \pm 4.752$  (0.431-25.079) and  $6.143 \pm 3.866$  (2.235-19.174), respectively ( $p = 0.725$ ). There was no significant difference between genders in control group.

Table 2. Comparison of urine 5-hydroxyindoleacetic acid/creatinine levels between dysfunctional voiding and control groups

	n <sup>a</sup>	Mean <sup>b</sup>	SD	p <sup>c</sup>
u5-HIAA/Cr	DV	69	6.139	3.652
	Control	48	6.374	4.329

DV: Dysfunctional voiding, u5-HIAA/Cr: Urine 5-hydroxyindoleacetic acid/creatinine, SD: Standard deviation

a: The number of children in dysfunctional voiding and control groups

b: Urine 5-hydroxyindoleacetic acid/creatinine (mg/g creatinine)

c: t test

Table 3. Comparison of pre-treatment urine 5-hydroxyindoleacetic acid/creatinine levels and those at the end of biofeedback therapy (6<sup>th</sup> month in completed the study)

	n <sup>a</sup>	Mean <sup>b</sup>	SD	p <sup>c</sup>
u5-HIAA/Cr	Baseline	45	6.249	4.132
	At the end of biofeedback therapy (6 <sup>th</sup> month)	45	6.190	4.715

u5-HIAA/Cr: Urinary 5-hydroxyindole acetic acid, SD: Standard deviation

a: The number of patients who completed the study

b: Urine 5-hydroxyindoleacetic acid/creatinine (mg/g creatinine)

c: Wilcoxon test

Table 4. Comparison of pre-treatment urine 5-hydroxyindoleacetic acid/creatinine levels and the levels at the 12<sup>th</sup> month (12<sup>th</sup> month in completed the study)

	n <sup>a</sup>	Mean <sup>b</sup>	SD	p <sup>c</sup>
u5-HIAA/Cr	Baseline	24	5.901	3.291
	12 <sup>th</sup> months	24	6.644	4.206

u5-HIAA/Cr: Urinary 5-hydroxyindole acetic acid, SD: Standard deviation

a: The number of patients who completed the study

b: Urine 5-hydroxyindoleacetic acid/creatinine (mg/g creatinine)

c: Wilcoxon test

There were 69 patients at the beginning for u5-HIAA/Cr levels, which declined to 45 and 24 patients at the 6<sup>th</sup> and 12<sup>th</sup> months, respectively. The mean u5-HIAA/Cr levels in DV group at baseline and at the end of biofeedback therapy (6<sup>th</sup> month) were  $6.249 \pm 4.132$  and  $6.19 \pm 4.715$ , respectively ( $p=0.951$ ) (Table 3). The mean u5-HIAA/Cr levels in DV group at baseline and at 12 months were  $5.901 \pm 3.291$  and  $6.644 \pm 4.206$ , respectively ( $p=0.557$ ) (Table 4). There was no significant difference in u5-HIAA/Cr levels between pre-treatment and post-treatment in DV group.

## Discussion

DV is one of the childhood urological problems that constitute a serious problem for families and children. Any neurogenic or non-neurogenic disease that increases intrabladder pressure adversely affects the upper urinary tract (4). DV is a non-neurogenic lower urinary tract disease which can lead to recurrent urinary tract infection, vesicoureteral reflux and chronic renal failure in children (14).

In the CNS, transmitters and modulators have various effects on contraction and relaxation in the lower urinary system (15). When the literature is examined, it appears that there are a number of studies investigating the relationship between 5-HT and voiding functions in animals (10,11,15,16). Studies on voiding function are related to the 5HT<sub>1A</sub> receptor. It has been shown that when injected in anesthetized rats with DV model, the 5-HT<sub>1A</sub> receptor agonist 8-OH-DPAT activated the voiding reflex, increased the frequency of bladder contractions, increased the voiding volume, reduced the bladder capacity, reduced intravesical pressure and decreased PVR (10). It has been demonstrated that the selective 5-HT<sub>1A</sub> agonist improved voiding efficacy in the rat model with voiding dysfunction. Serotonin which excreted with urine decomposes to 5-HIAA.

In the DV etiology, there is an inadequacy of complete relaxation of the pelvic floor muscles or urinary sphincter during voiding (17). We still do not know if there is a problem at the level of neurotransmitter or neurotransmitters metabolite in the CNS. There is no study in humans that evaluates this etiology.

We evaluated this relationship, but we could not find a significant result. We did not find significant differences in u5-HIAA/Cr levels between DV and control groups. There was no significant difference in u5-HIAA/Cr levels between pre-treatment and post-treatment in DV group.

Biofeedback therapy is a simple, effective, well tolerated and non-invasive treatment method for children with DV (18). Krzemińska et al. (19) reported biofeedback therapy outcomes in children with DV. After 2 months of biofeedback therapy, children had a 50.7% improvement in daytime incontinence and 53.65% improvement in enuresis. Kibar et al. (20) reported results of

biofeedback treatment in children aged 5-14 years with DV and vesicoureteral reflux. They reported significant, improvements in enuresis, daytime wetting, constipation, frequency and urgency (82%, 70%, 78%, 76% and 71%, respectively) in older children who received biofeedback therapy.

Shei Dei Yang et al. (21) reported outcomes of a short course biofeedback treatment in children with DV. They showed a 90% improvement in UF-EMG pattern. In addition, PVR decreased from 54.5 to 21.3 mL with biofeedback therapy. Biofeedback therapy has been applied successfully in our clinic for many years and we have many studies in this field (2,18,20). We found a significant improvement in DVISS, UF-EMG pattern and PVR as in other studies.

## Study Limitations

In our study, we could measure the serotonin metabolite instead of serotonin. This situation can be regarded as the main limitation. We used urine specimens because it was difficult to get blood samples several times in children. Urine 5-HIAA results may be affected by the ingestion of tryptophan/serotonin-rich foods (avocados, bananas, kiwi fruit, melons, nuts, tomatoes, etc.) and certain medications and supplements (acetaminophen). It is important that these substances be avoided for 24 to 72 hours prior to urine sampling. We failed to comply with this rule.

## Conclusion

Urine 5-HIAA has no place in the evaluation of the etiology and treatment success in childhood DV. New studies are needed to get more information about the role of neuromodulators in the etiology and treatment of DV.

## Ethics

**Ethics Committee Approval:** This study was approved by the Gülhane Military Medical Academy Ethics Committee (approval number: 15, date: 3 April 2013).

**Informed Consent:** Consent form was filled out by all participants.

**Peer-reviewed:** Externally peer-reviewed.

## Authorship Contributions

Surgical and Medical Practices: B.T., G.E., Concept: B.T., Y.K., Design: B.T., B.K., T.E., Data Collection or Processing: B.T., G.E., Analysis or Interpretation: H.C.I., Y.K., M.M.D., Literature Search: B.T., B.K., Writing: B.T.

**Conflict of Interest:** No conflict of interest was declared by the authors.

**Financial Disclosure:** The authors declared that this study received no financial support.

## References

1. Austin PF, Bauer SB, Bower W, Chase J, Franco I, Hoebke P, Rittig S, Walle JV, von Gontard A, Wright A, Yang SS, Nevés T. The standardization of terminology of lower urinary tract function in children and adolescents: Update report from the standardization committee of the International Children's Continence Society. *Neurourol Urodyn* 2016;35:471-481.
2. Ergin G, Kibar Y, Ebioloğlu T, Irkilata HC, Kopru B, Kaya E, Uyanık M, Tapan S, Dayanc MM. The role of urinary nerve growth factor for the diagnosis and assessment of the biofeedback success in children with dysfunctional voiding. *J Pediatr Urol* 2016;12:118.
3. Van Batavia JP, Combs AJ, Fast AM, Glassberg KI. Use of non-invasive uroflowmetry with simultaneous electromyography to monitor patient response to treatment for lower urinary tract conditions. *J Pediatr Urol* 2014;10:532-537.
4. Sillén U, Brandström P, Jodal U, Holmdahl G, Sandin A, Sjöberg I, Hansson S. The Swedish reflux trial in children: v. Bladder dysfunction. *J Urol* 2010;184:298-304.
5. Dayanc MM, Kibar Y, Irkilata HC, Sancaktutar AA, Ebioloğlu T, Gur A, Ergin G, Alp BF, Gok F. Effect of Voided Volume on Voiding Patterns and Reliability of Uroflowmetry-Electromyography Results in Children with Lower Urinary Tract Dysfunction. *Low Urin Tract Symptoms* 2017;9:46-51.
6. de Groat WC, Yoshimura N. Pharmacology of the lower urinary tract. *Annu Rev Pharmacol Toxicol* 2001;41:691-721.
7. Andersson KE. Treatment of the overactive bladder: possible central nervous system drug targets. *Urology* 2002;59(5 Suppl 1):18-24.
8. Boyer EW, Shannon M. The serotonin syndrome. *N Engl J Med* 2005;352:1112-1120.
9. van Dijk SC, de Herder WW, Kwekkeboom DJ, Zillikens MC, Feelders RA, van Schaik RH, van Driel M, van Leeuwen JP. 5-HIAA excretion is not associated with bone metabolism in carcinoid syndrome patients. *Bone* 2012;50:1260-1265.
10. Cheng CL, de Groat WC. Role of 5-HT1A receptors in control of lower urinary tract function in anesthetized rats. *Am J Physiol Renal Physiol* 2010;298:771-778.
11. Dolber PC, Gu B, Zhang X, Fraser MO, Thor KB, Reiter JP. Activation of the external urethral sphincter central pattern generator by a 5-HT(1A) receptor agonist in rats with chronic spinal cord injury. *Am J Physiol Regul Integr Comp Physiol* 2007;292:1699-1706.
12. Tellez MR, Mamikunian G, O'Dorisio TM, Vinik AI, Woltering EA. A single fasting plasma 5-HIAA value correlates with 24-hour urinary 5-HIAA values and other biomarkers in midgut neuroendocrine tumors (NETs). *Pancreas* 2013;42:405-410.
13. Jangjoo A, Varasteh AR, Mehrabi Bahar M, Tayyebi Meibodi N, Esmaili H, Nazeri N, Aliakbarian M, Azizi SH. Is urinary 5-hydroxyindoleacetic acid helpful for early diagnosis of acute appendicitis? *Am J Emerg Med* 2012;30:540-544.
14. Leclair MD, Héroudy Y. Non-neurogenic elimination disorders in children. *J Pediatr Urol* 2010;6:338-345.
15. Andersson KE, Wein AJ. Pharmacology of the lower urinary tract: basis for current and future treatments of urinary incontinence. *Pharmacol Rev* 2004;56:581-631.
16. Chen SC, Cheng CL, Fan WJ, Chen JJ, Lai CH, Peng CW. Effect of a 5-HT1A receptor agonist (8-OH-DPAT) on external urethral sphincter activity in a rat model of pudendal nerve injury. *Am J Physiol Regul Integr Comp Physiol* 2011;301:225-235.
17. Ellsworth PI, Merguerian PA, Copening ME. Sexual abuse: another causative factor in dysfunctional voiding. *J Urol* 1995;153:773-776.
18. Kibar Y, Demir E, Irkilata C, Ors O, Gok F, Dayanc M. Effect of biofeedback treatment on spinning top urethra in children with voiding dysfunction. *Urology* 2007;70:781-784.
19. Krzemińska K, Maternik M, Drożyńska-Duklas M, Szcześniak P, Czarniak P, Gołębiewski A, Zurowska A. High efficacy of biofeedback therapy for treatment of dysfunctional voiding in children. *Cent European J Urol* 2012;65:212-215.
20. Kibar Y, Ors O, Demir E, Kalman S, Sakallioğlu O, Dayanc M. Results of biofeedback treatment on reflux resolution rates in children with dysfunctional voiding and vesicoureteral reflux. *Urology* 2007;70:563-566.
21. Shei Dei Yang S, Wang CC. Outpatient biofeedback relaxation of the pelvic floor in treating pediatric dysfunctional voiding: a short-course program is effective. *Urol Int* 2005;74:118-122.